Relay Therapeutics (NASDAQ: RLAY) grants CFO 400,000 stock options

Rhea-AI Filing Summary

Relay Therapeutics reported that its Chief Financial Officer, Thomas Catinazzo, received a new stock option grant. On 01/13/2026, he was awarded a stock option to buy 400,000 shares of common stock at $7.94 per share. After this grant, he beneficially owns 400,000 derivative securities directly.

The option shares will vest in sixteen equal quarterly installments after January 13, 2026, and each installment requires his continued service with the company through the applicable vesting date. This filing records the award and resulting beneficial ownership rather than any share sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Catinazzo Thomas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	400,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 400,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Catinazzo Thomas

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.94	01/13/2026		A		400,000		(1)	01/12/2036	Common Stock	400,000	$0.00	400,000	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after January 13, 2026, subject to the reporting person's continued service with the Issuer through each vesting date.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Relay Therapeutics (RLAY) disclose in this Form 4?

The filing shows that Chief Financial Officer Thomas Catinazzo was granted a stock option (right to buy) covering 400,000 shares of Relay Therapeutics common stock at an exercise price of $7.94 per share on 01/13/2026.

How many Relay Therapeutics (RLAY) shares are covered by the new stock option?

The stock option granted to the CFO covers 400,000 shares of Relay Therapeutics common stock, as disclosed in Table II of the Form 4.

What is the exercise price and term of the CFO’s Relay Therapeutics stock option?

The option has a conversion or exercise price of $7.94 per share and an expiration date of 01/12/2036, with the underlying security described as Relay Therapeutics common stock.

What is the vesting schedule for the Relay Therapeutics CFO’s 400,000-share option?

According to the footnote, the 400,000 shares underlying the stock option vest in sixteen (16) equal quarterly installments after January 13, 2026, and each installment is subject to the reporting person’s continued service with Relay Therapeutics through the relevant vesting date.

How many derivative securities does the Relay Therapeutics CFO own after this transaction?

Following the reported grant, the CFO beneficially owns 400,000 derivative securities (stock options) directly, as shown in the “Number of derivative Securities Beneficially Owned Following Reported Transaction(s)” column.

Is the Relay Therapeutics CFO’s Form 4 transaction a purchase or a grant?

The transaction code is “A” (acquisition) for a stock option (right to buy), with the price of the derivative listed as $0.00. This indicates a grant of options rather than an open-market purchase of shares.